nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—colon cancer	0.492	1	CbGaD
Carfilzomib—Peripheral motor neuropathy—Vincristine—colon cancer	0.00855	0.0606	CcSEcCtD
Carfilzomib—PSMB10—lymphoid tissue—colon cancer	0.00607	0.0569	CbGeAlD
Carfilzomib—PSMB10—digestive system—colon cancer	0.00599	0.0562	CbGeAlD
Carfilzomib—Tumour lysis syndrome—Vincristine—colon cancer	0.00562	0.0399	CcSEcCtD
Carfilzomib—Tumour lysis syndrome—Irinotecan—colon cancer	0.00548	0.0388	CcSEcCtD
Carfilzomib—PSMB1—embryo—colon cancer	0.0048	0.045	CbGeAlD
Carfilzomib—Multi-organ failure—Vincristine—colon cancer	0.00479	0.034	CcSEcCtD
Carfilzomib—PSMB2—embryo—colon cancer	0.00469	0.0439	CbGeAlD
Carfilzomib—PSMB10—liver—colon cancer	0.00447	0.0419	CbGeAlD
Carfilzomib—PSMB5—smooth muscle tissue—colon cancer	0.00432	0.0405	CbGeAlD
Carfilzomib—PSMB10—Vinblastine—Vincristine—colon cancer	0.00415	0.643	CbGdCrCtD
Carfilzomib—PSMB1—smooth muscle tissue—colon cancer	0.00378	0.0354	CbGeAlD
Carfilzomib—PSMB2—smooth muscle tissue—colon cancer	0.00369	0.0345	CbGeAlD
Carfilzomib—Herpes virus infection—Capecitabine—colon cancer	0.00367	0.026	CcSEcCtD
Carfilzomib—PSMB1—renal system—colon cancer	0.00364	0.0341	CbGeAlD
Carfilzomib—PSMB8—bone marrow—colon cancer	0.00356	0.0334	CbGeAlD
Carfilzomib—Peripheral sensory neuropathy—Capecitabine—colon cancer	0.00356	0.0253	CcSEcCtD
Carfilzomib—PSMB2—renal system—colon cancer	0.00355	0.0333	CbGeAlD
Carfilzomib—PSMB10—lymph node—colon cancer	0.00342	0.0321	CbGeAlD
Carfilzomib—PSMB8—vagina—colon cancer	0.00341	0.032	CbGeAlD
Carfilzomib—PSMB5—bone marrow—colon cancer	0.00315	0.0295	CbGeAlD
Carfilzomib—PSMB1—lymphoid tissue—colon cancer	0.00302	0.0283	CbGeAlD
Carfilzomib—PSMB5—vagina—colon cancer	0.00301	0.0282	CbGeAlD
Carfilzomib—PSMB1—digestive system—colon cancer	0.00298	0.028	CbGeAlD
Carfilzomib—Lymphopenia—Irinotecan—colon cancer	0.00297	0.0211	CcSEcCtD
Carfilzomib—PSMB2—lymphoid tissue—colon cancer	0.00295	0.0276	CbGeAlD
Carfilzomib—PSMB2—digestive system—colon cancer	0.00291	0.0273	CbGeAlD
Carfilzomib—PSMB8—liver—colon cancer	0.00288	0.027	CbGeAlD
Carfilzomib—PSMB1—bone marrow—colon cancer	0.00275	0.0258	CbGeAlD
Carfilzomib—Tumour lysis syndrome—Methotrexate—colon cancer	0.00273	0.0194	CcSEcCtD
Carfilzomib—PSMB2—bone marrow—colon cancer	0.00268	0.0251	CbGeAlD
Carfilzomib—PSMB1—vagina—colon cancer	0.00263	0.0247	CbGeAlD
Carfilzomib—PSMB2—vagina—colon cancer	0.00257	0.0241	CbGeAlD
Carfilzomib—PSMB5—liver—colon cancer	0.00254	0.0238	CbGeAlD
Carfilzomib—Hypomagnesaemia—Irinotecan—colon cancer	0.00239	0.017	CcSEcCtD
Carfilzomib—PSMB8—Vinorelbine—Vincristine—colon cancer	0.0023	0.357	CbGdCrCtD
Carfilzomib—PSMB1—liver—colon cancer	0.00222	0.0208	CbGeAlD
Carfilzomib—PSMB8—lymph node—colon cancer	0.00221	0.0207	CbGeAlD
Carfilzomib—PSMB2—liver—colon cancer	0.00217	0.0203	CbGeAlD
Carfilzomib—Neuritis—Vincristine—colon cancer	0.00209	0.0148	CcSEcCtD
Carfilzomib—Lymphopenia—Capecitabine—colon cancer	0.00199	0.0141	CcSEcCtD
Carfilzomib—PSMB5—lymph node—colon cancer	0.00195	0.0183	CbGeAlD
Carfilzomib—Myocardial ischaemia—Irinotecan—colon cancer	0.00189	0.0134	CcSEcCtD
Carfilzomib—Myocardial ischaemia—Fluorouracil—colon cancer	0.00181	0.0128	CcSEcCtD
Carfilzomib—PSMB1—lymph node—colon cancer	0.0017	0.016	CbGeAlD
Carfilzomib—PSMB2—lymph node—colon cancer	0.00166	0.0156	CbGeAlD
Carfilzomib—Bacterial infection—Methotrexate—colon cancer	0.00164	0.0116	CcSEcCtD
Carfilzomib—Hypomagnesaemia—Capecitabine—colon cancer	0.0016	0.0114	CcSEcCtD
Carfilzomib—Hypercalcaemia—Capecitabine—colon cancer	0.00146	0.0104	CcSEcCtD
Carfilzomib—Sepsis—Irinotecan—colon cancer	0.00132	0.00936	CcSEcCtD
Carfilzomib—Myocardial ischaemia—Capecitabine—colon cancer	0.00127	0.00898	CcSEcCtD
Carfilzomib—Sepsis—Fluorouracil—colon cancer	0.00126	0.00896	CcSEcCtD
Carfilzomib—Hepatic failure—Vincristine—colon cancer	0.00126	0.00894	CcSEcCtD
Carfilzomib—Lopinavir—ABCB1—colon cancer	0.00121	0.543	CrCbGaD
Carfilzomib—ABCB1—blood vessel—colon cancer	0.0012	0.0113	CbGeAlD
Carfilzomib—Renal failure acute—Irinotecan—colon cancer	0.0012	0.00848	CcSEcCtD
Carfilzomib—Hyponatraemia—Vincristine—colon cancer	0.00114	0.00807	CcSEcCtD
Carfilzomib—Pain in extremity—Vincristine—colon cancer	0.00113	0.00804	CcSEcCtD
Carfilzomib—Hyponatraemia—Irinotecan—colon cancer	0.00111	0.00786	CcSEcCtD
Carfilzomib—Cardiac arrest—Vincristine—colon cancer	0.00108	0.00764	CcSEcCtD
Carfilzomib—Cardiac arrest—Irinotecan—colon cancer	0.00105	0.00744	CcSEcCtD
Carfilzomib—Blood creatinine increased—Irinotecan—colon cancer	0.00103	0.00733	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Vincristine—colon cancer	0.00102	0.00724	CcSEcCtD
Carfilzomib—Ritonavir—ABCB1—colon cancer	0.00102	0.457	CrCbGaD
Carfilzomib—Cardiac arrest—Fluorouracil—colon cancer	0.00101	0.00713	CcSEcCtD
Carfilzomib—Hypokalaemia—Irinotecan—colon cancer	0.001	0.00712	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Irinotecan—colon cancer	0.000994	0.00705	CcSEcCtD
Carfilzomib—Neutropenia—Vincristine—colon cancer	0.000916	0.0065	CcSEcCtD
Carfilzomib—Neutropenia—Irinotecan—colon cancer	0.000892	0.00633	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Irinotecan—colon cancer	0.000886	0.00629	CcSEcCtD
Carfilzomib—Sepsis—Capecitabine—colon cancer	0.000883	0.00626	CcSEcCtD
Carfilzomib—Pneumonia—Vincristine—colon cancer	0.000878	0.00623	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Vincristine—colon cancer	0.000861	0.00611	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Vincristine—colon cancer	0.000856	0.00607	CcSEcCtD
Carfilzomib—Pneumonia—Irinotecan—colon cancer	0.000855	0.00607	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Fluorouracil—colon cancer	0.000849	0.00602	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Irinotecan—colon cancer	0.000838	0.00595	CcSEcCtD
Carfilzomib—Renal failure—Irinotecan—colon cancer	0.000836	0.00593	CcSEcCtD
Carfilzomib—Hepatic failure—Capecitabine—colon cancer	0.000822	0.00583	CcSEcCtD
Carfilzomib—Pneumonia—Fluorouracil—colon cancer	0.000819	0.00581	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Fluorouracil—colon cancer	0.000803	0.00569	CcSEcCtD
Carfilzomib—Renal failure acute—Capecitabine—colon cancer	0.0008	0.00567	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Fluorouracil—colon cancer	0.000798	0.00566	CcSEcCtD
Carfilzomib—Hypoaesthesia—Vincristine—colon cancer	0.00078	0.00553	CcSEcCtD
Carfilzomib—Hyponatraemia—Capecitabine—colon cancer	0.000742	0.00526	CcSEcCtD
Carfilzomib—Pain in extremity—Capecitabine—colon cancer	0.000739	0.00524	CcSEcCtD
Carfilzomib—Cardiac disorder—Vincristine—colon cancer	0.000728	0.00516	CcSEcCtD
Carfilzomib—Hypoaesthesia—Fluorouracil—colon cancer	0.000728	0.00516	CcSEcCtD
Carfilzomib—ABCB1—embryo—colon cancer	0.000716	0.00671	CbGeAlD
Carfilzomib—Cardiac disorder—Irinotecan—colon cancer	0.000709	0.00503	CcSEcCtD
Carfilzomib—Cardiac arrest—Capecitabine—colon cancer	0.000702	0.00498	CcSEcCtD
Carfilzomib—Blood creatinine increased—Capecitabine—colon cancer	0.000692	0.00491	CcSEcCtD
Carfilzomib—Chills—Irinotecan—colon cancer	0.000685	0.00486	CcSEcCtD
Carfilzomib—Hypokalaemia—Capecitabine—colon cancer	0.000672	0.00477	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.000665	0.00472	CcSEcCtD
Carfilzomib—Back pain—Vincristine—colon cancer	0.00066	0.00468	CcSEcCtD
Carfilzomib—Sepsis—Methotrexate—colon cancer	0.000657	0.00466	CcSEcCtD
Carfilzomib—Back pain—Irinotecan—colon cancer	0.000643	0.00456	CcSEcCtD
Carfilzomib—Muscle spasms—Irinotecan—colon cancer	0.000639	0.00453	CcSEcCtD
Carfilzomib—Anaemia—Vincristine—colon cancer	0.000631	0.00447	CcSEcCtD
Carfilzomib—Anaemia—Irinotecan—colon cancer	0.000614	0.00436	CcSEcCtD
Carfilzomib—Hepatic failure—Methotrexate—colon cancer	0.000612	0.00434	CcSEcCtD
Carfilzomib—Leukopenia—Vincristine—colon cancer	0.000611	0.00433	CcSEcCtD
Carfilzomib—Neutropenia—Capecitabine—colon cancer	0.000597	0.00423	CcSEcCtD
Carfilzomib—Renal failure acute—Methotrexate—colon cancer	0.000596	0.00422	CcSEcCtD
Carfilzomib—Leukopenia—Irinotecan—colon cancer	0.000595	0.00422	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Capecitabine—colon cancer	0.000593	0.00421	CcSEcCtD
Carfilzomib—Hypertension—Vincristine—colon cancer	0.000589	0.00418	CcSEcCtD
Carfilzomib—Anaemia—Fluorouracil—colon cancer	0.000588	0.00417	CcSEcCtD
Carfilzomib—ABCB1—epithelium—colon cancer	0.000584	0.00548	CbGeAlD
Carfilzomib—Cough—Irinotecan—colon cancer	0.00058	0.00411	CcSEcCtD
Carfilzomib—Hyperglycaemia—Capecitabine—colon cancer	0.000576	0.00408	CcSEcCtD
Carfilzomib—Hypertension—Irinotecan—colon cancer	0.000574	0.00407	CcSEcCtD
Carfilzomib—Pneumonia—Capecitabine—colon cancer	0.000572	0.00406	CcSEcCtD
Carfilzomib—Leukopenia—Fluorouracil—colon cancer	0.00057	0.00404	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Capecitabine—colon cancer	0.000561	0.00398	CcSEcCtD
Carfilzomib—Renal failure—Capecitabine—colon cancer	0.000559	0.00397	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Capecitabine—colon cancer	0.000558	0.00396	CcSEcCtD
Carfilzomib—Infection—Vincristine—colon cancer	0.000553	0.00392	CcSEcCtD
Carfilzomib—Thrombocytopenia—Vincristine—colon cancer	0.000545	0.00387	CcSEcCtD
Carfilzomib—ABCB1—renal system—colon cancer	0.000542	0.00508	CbGeAlD
Carfilzomib—Infection—Irinotecan—colon cancer	0.000539	0.00382	CcSEcCtD
Carfilzomib—Thrombocytopenia—Irinotecan—colon cancer	0.000531	0.00377	CcSEcCtD
Carfilzomib—Anorexia—Vincristine—colon cancer	0.000531	0.00377	CcSEcCtD
Carfilzomib—Anorexia—Irinotecan—colon cancer	0.000517	0.00367	CcSEcCtD
Carfilzomib—Infection—Fluorouracil—colon cancer	0.000516	0.00366	CcSEcCtD
Carfilzomib—Thrombocytopenia—Fluorouracil—colon cancer	0.000509	0.00361	CcSEcCtD
Carfilzomib—Hypoaesthesia—Capecitabine—colon cancer	0.000508	0.00361	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Vincristine—colon cancer	0.000507	0.0036	CcSEcCtD
Carfilzomib—Insomnia—Vincristine—colon cancer	0.000504	0.00357	CcSEcCtD
Carfilzomib—Oedema peripheral—Capecitabine—colon cancer	0.000503	0.00357	CcSEcCtD
Carfilzomib—Anorexia—Fluorouracil—colon cancer	0.000495	0.00351	CcSEcCtD
Carfilzomib—Insomnia—Irinotecan—colon cancer	0.000491	0.00348	CcSEcCtD
Carfilzomib—Decreased appetite—Vincristine—colon cancer	0.000484	0.00343	CcSEcCtD
Carfilzomib—Dyspnoea—Irinotecan—colon cancer	0.000484	0.00343	CcSEcCtD
Carfilzomib—Fatigue—Vincristine—colon cancer	0.00048	0.00341	CcSEcCtD
Carfilzomib—Pain—Vincristine—colon cancer	0.000476	0.00338	CcSEcCtD
Carfilzomib—Constipation—Vincristine—colon cancer	0.000476	0.00338	CcSEcCtD
Carfilzomib—Cardiac disorder—Capecitabine—colon cancer	0.000474	0.00336	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000473	0.00336	CcSEcCtD
Carfilzomib—Decreased appetite—Irinotecan—colon cancer	0.000471	0.00334	CcSEcCtD
Carfilzomib—Insomnia—Fluorouracil—colon cancer	0.00047	0.00333	CcSEcCtD
Carfilzomib—Fatigue—Irinotecan—colon cancer	0.000468	0.00332	CcSEcCtD
Carfilzomib—Constipation—Irinotecan—colon cancer	0.000464	0.00329	CcSEcCtD
Carfilzomib—Pain—Irinotecan—colon cancer	0.000464	0.00329	CcSEcCtD
Carfilzomib—Dyspnoea—Fluorouracil—colon cancer	0.000463	0.00328	CcSEcCtD
Carfilzomib—Chills—Capecitabine—colon cancer	0.000458	0.00325	CcSEcCtD
Carfilzomib—Decreased appetite—Fluorouracil—colon cancer	0.000452	0.0032	CcSEcCtD
Carfilzomib—ABCB1—lymphoid tissue—colon cancer	0.00045	0.00422	CbGeAlD
Carfilzomib—ABCB1—digestive system—colon cancer	0.000445	0.00417	CbGeAlD
Carfilzomib—Neutropenia—Methotrexate—colon cancer	0.000444	0.00315	CcSEcCtD
Carfilzomib—Pain—Fluorouracil—colon cancer	0.000444	0.00315	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Methotrexate—colon cancer	0.000442	0.00313	CcSEcCtD
Carfilzomib—Body temperature increased—Vincristine—colon cancer	0.00044	0.00312	CcSEcCtD
Carfilzomib—Back pain—Capecitabine—colon cancer	0.00043	0.00305	CcSEcCtD
Carfilzomib—Body temperature increased—Irinotecan—colon cancer	0.000429	0.00304	CcSEcCtD
Carfilzomib—Muscle spasms—Capecitabine—colon cancer	0.000428	0.00303	CcSEcCtD
Carfilzomib—Pneumonia—Methotrexate—colon cancer	0.000426	0.00302	CcSEcCtD
Carfilzomib—Renal failure—Methotrexate—colon cancer	0.000417	0.00295	CcSEcCtD
Carfilzomib—Anaemia—Capecitabine—colon cancer	0.000411	0.00292	CcSEcCtD
Carfilzomib—Body temperature increased—Fluorouracil—colon cancer	0.000411	0.00291	CcSEcCtD
Carfilzomib—ABCB1—bone marrow—colon cancer	0.00041	0.00384	CbGeAlD
Carfilzomib—Asthenia—Vincristine—colon cancer	0.0004	0.00283	CcSEcCtD
Carfilzomib—Leukopenia—Capecitabine—colon cancer	0.000398	0.00282	CcSEcCtD
Carfilzomib—ABCB1—vagina—colon cancer	0.000393	0.00368	CbGeAlD
Carfilzomib—Asthenia—Irinotecan—colon cancer	0.000389	0.00276	CcSEcCtD
Carfilzomib—Cough—Capecitabine—colon cancer	0.000388	0.00275	CcSEcCtD
Carfilzomib—Hypertension—Capecitabine—colon cancer	0.000384	0.00272	CcSEcCtD
Carfilzomib—Diarrhoea—Vincristine—colon cancer	0.000381	0.0027	CcSEcCtD
Carfilzomib—Arthralgia—Capecitabine—colon cancer	0.000379	0.00269	CcSEcCtD
Carfilzomib—Diarrhoea—Irinotecan—colon cancer	0.000371	0.00263	CcSEcCtD
Carfilzomib—Dizziness—Vincristine—colon cancer	0.000368	0.00261	CcSEcCtD
Carfilzomib—Infection—Capecitabine—colon cancer	0.000361	0.00256	CcSEcCtD
Carfilzomib—Dizziness—Irinotecan—colon cancer	0.000359	0.00254	CcSEcCtD
Carfilzomib—Diarrhoea—Fluorouracil—colon cancer	0.000355	0.00252	CcSEcCtD
Carfilzomib—Thrombocytopenia—Capecitabine—colon cancer	0.000355	0.00252	CcSEcCtD
Carfilzomib—Vomiting—Vincristine—colon cancer	0.000354	0.00251	CcSEcCtD
Carfilzomib—Cardiac disorder—Methotrexate—colon cancer	0.000353	0.0025	CcSEcCtD
Carfilzomib—Headache—Vincristine—colon cancer	0.000349	0.00247	CcSEcCtD
Carfilzomib—Anorexia—Capecitabine—colon cancer	0.000346	0.00245	CcSEcCtD
Carfilzomib—Vomiting—Irinotecan—colon cancer	0.000345	0.00245	CcSEcCtD
Carfilzomib—Dizziness—Fluorouracil—colon cancer	0.000344	0.00244	CcSEcCtD
Carfilzomib—Chills—Methotrexate—colon cancer	0.000341	0.00242	CcSEcCtD
Carfilzomib—Headache—Irinotecan—colon cancer	0.00034	0.00241	CcSEcCtD
Carfilzomib—ABCB1—liver—colon cancer	0.000331	0.0031	CbGeAlD
Carfilzomib—Nausea—Vincristine—colon cancer	0.000331	0.00235	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000331	0.00235	CcSEcCtD
Carfilzomib—Vomiting—Fluorouracil—colon cancer	0.00033	0.00234	CcSEcCtD
Carfilzomib—Insomnia—Capecitabine—colon cancer	0.000328	0.00233	CcSEcCtD
Carfilzomib—Headache—Fluorouracil—colon cancer	0.000325	0.00231	CcSEcCtD
Carfilzomib—Dyspnoea—Capecitabine—colon cancer	0.000324	0.0023	CcSEcCtD
Carfilzomib—Nausea—Irinotecan—colon cancer	0.000322	0.00228	CcSEcCtD
Carfilzomib—Back pain—Methotrexate—colon cancer	0.00032	0.00227	CcSEcCtD
Carfilzomib—Decreased appetite—Capecitabine—colon cancer	0.000316	0.00224	CcSEcCtD
Carfilzomib—Fatigue—Capecitabine—colon cancer	0.000313	0.00222	CcSEcCtD
Carfilzomib—Pain—Capecitabine—colon cancer	0.00031	0.0022	CcSEcCtD
Carfilzomib—Constipation—Capecitabine—colon cancer	0.00031	0.0022	CcSEcCtD
Carfilzomib—Nausea—Fluorouracil—colon cancer	0.000309	0.00219	CcSEcCtD
Carfilzomib—Anaemia—Methotrexate—colon cancer	0.000306	0.00217	CcSEcCtD
Carfilzomib—Leukopenia—Methotrexate—colon cancer	0.000296	0.0021	CcSEcCtD
Carfilzomib—Cough—Methotrexate—colon cancer	0.000289	0.00205	CcSEcCtD
Carfilzomib—Body temperature increased—Capecitabine—colon cancer	0.000287	0.00204	CcSEcCtD
Carfilzomib—Arthralgia—Methotrexate—colon cancer	0.000282	0.002	CcSEcCtD
Carfilzomib—Infection—Methotrexate—colon cancer	0.000268	0.0019	CcSEcCtD
Carfilzomib—Thrombocytopenia—Methotrexate—colon cancer	0.000265	0.00188	CcSEcCtD
Carfilzomib—Asthenia—Capecitabine—colon cancer	0.00026	0.00185	CcSEcCtD
Carfilzomib—Anorexia—Methotrexate—colon cancer	0.000258	0.00183	CcSEcCtD
Carfilzomib—ABCB1—lymph node—colon cancer	0.000254	0.00238	CbGeAlD
Carfilzomib—Diarrhoea—Capecitabine—colon cancer	0.000248	0.00176	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000246	0.00175	CcSEcCtD
Carfilzomib—Insomnia—Methotrexate—colon cancer	0.000244	0.00173	CcSEcCtD
Carfilzomib—Dyspnoea—Methotrexate—colon cancer	0.000241	0.00171	CcSEcCtD
Carfilzomib—Dizziness—Capecitabine—colon cancer	0.00024	0.0017	CcSEcCtD
Carfilzomib—Decreased appetite—Methotrexate—colon cancer	0.000235	0.00167	CcSEcCtD
Carfilzomib—Fatigue—Methotrexate—colon cancer	0.000233	0.00165	CcSEcCtD
Carfilzomib—Pain—Methotrexate—colon cancer	0.000231	0.00164	CcSEcCtD
Carfilzomib—Vomiting—Capecitabine—colon cancer	0.000231	0.00164	CcSEcCtD
Carfilzomib—Headache—Capecitabine—colon cancer	0.000227	0.00161	CcSEcCtD
Carfilzomib—Nausea—Capecitabine—colon cancer	0.000216	0.00153	CcSEcCtD
Carfilzomib—Body temperature increased—Methotrexate—colon cancer	0.000214	0.00152	CcSEcCtD
Carfilzomib—Asthenia—Methotrexate—colon cancer	0.000194	0.00138	CcSEcCtD
Carfilzomib—Diarrhoea—Methotrexate—colon cancer	0.000185	0.00131	CcSEcCtD
Carfilzomib—Dizziness—Methotrexate—colon cancer	0.000179	0.00127	CcSEcCtD
Carfilzomib—Vomiting—Methotrexate—colon cancer	0.000172	0.00122	CcSEcCtD
Carfilzomib—Headache—Methotrexate—colon cancer	0.000169	0.0012	CcSEcCtD
Carfilzomib—Nausea—Methotrexate—colon cancer	0.000161	0.00114	CcSEcCtD
Carfilzomib—PSMB5—Immune System—CDKN1A—colon cancer	2.8e-05	0.000111	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CDKN1A—colon cancer	2.8e-05	0.000111	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	2.77e-05	0.00011	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—EGFR—colon cancer	2.76e-05	0.00011	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CDKN1A—colon cancer	2.76e-05	0.000109	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—EGFR—colon cancer	2.75e-05	0.000109	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—APC—colon cancer	2.72e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—APC—colon cancer	2.72e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—APC—colon cancer	2.72e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—EP300—colon cancer	2.71e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—EP300—colon cancer	2.7e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—APC—colon cancer	2.69e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EP300—colon cancer	2.66e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EP300—colon cancer	2.66e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EP300—colon cancer	2.66e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—AKT1—colon cancer	2.65e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—AKT1—colon cancer	2.65e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—AKT1—colon cancer	2.65e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CTNNB1—colon cancer	2.64e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CTNNB1—colon cancer	2.64e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CTNNB1—colon cancer	2.64e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EP300—colon cancer	2.62e-05	0.000104	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	2.62e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—AKT1—colon cancer	2.61e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—KRAS—colon cancer	2.61e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CTNNB1—colon cancer	2.61e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—KRAS—colon cancer	2.6e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—PIK3CA—colon cancer	2.6e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—SRC—colon cancer	2.59e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—SRC—colon cancer	2.59e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—SRC—colon cancer	2.59e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—PIK3CA—colon cancer	2.58e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CDKN1A—colon cancer	2.58e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CDKN1A—colon cancer	2.58e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CDKN1A—colon cancer	2.58e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—BRAF—colon cancer	2.56e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—BRAF—colon cancer	2.56e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—BRAF—colon cancer	2.56e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—SRC—colon cancer	2.55e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CDKN1A—colon cancer	2.54e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CASP3—colon cancer	2.53e-05	0.0001	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—BRAF—colon cancer	2.52e-05	0.0001	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CASP3—colon cancer	2.52e-05	0.0001	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—NRAS—colon cancer	2.49e-05	9.87e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—NRAS—colon cancer	2.49e-05	9.87e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—NRAS—colon cancer	2.49e-05	9.87e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTGS2—colon cancer	2.47e-05	9.81e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTGS2—colon cancer	2.47e-05	9.81e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTGS2—colon cancer	2.47e-05	9.81e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCND1—colon cancer	2.47e-05	9.78e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EP300—colon cancer	2.46e-05	9.74e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EP300—colon cancer	2.46e-05	9.74e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EP300—colon cancer	2.46e-05	9.74e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCND1—colon cancer	2.45e-05	9.73e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—NRAS—colon cancer	2.45e-05	9.73e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CTNNB1—colon cancer	2.44e-05	9.68e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTGS2—colon cancer	2.44e-05	9.67e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CTNNB1—colon cancer	2.43e-05	9.64e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EP300—colon cancer	2.42e-05	9.6e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	2.41e-05	9.55e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—HRAS—colon cancer	2.4e-05	9.53e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—PIK3CA—colon cancer	2.4e-05	9.51e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—HRAS—colon cancer	2.39e-05	9.48e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—SRC—colon cancer	2.39e-05	9.47e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—SRC—colon cancer	2.39e-05	9.47e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—SRC—colon cancer	2.39e-05	9.47e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—PIK3CA—colon cancer	2.39e-05	9.46e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CDKN1A—colon cancer	2.39e-05	9.46e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CDKN1A—colon cancer	2.37e-05	9.41e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—SRC—colon cancer	2.35e-05	9.34e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	2.33e-05	9.24e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MYC—colon cancer	2.31e-05	9.14e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MYC—colon cancer	2.31e-05	9.14e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MYC—colon cancer	2.31e-05	9.14e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—NRAS—colon cancer	2.3e-05	9.11e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—NRAS—colon cancer	2.3e-05	9.11e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—NRAS—colon cancer	2.3e-05	9.11e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MYC—colon cancer	2.27e-05	9.01e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EP300—colon cancer	2.27e-05	9e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EGFR—colon cancer	2.27e-05	8.99e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EGFR—colon cancer	2.27e-05	8.99e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EGFR—colon cancer	2.27e-05	8.99e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—NRAS—colon cancer	2.27e-05	8.98e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EP300—colon cancer	2.26e-05	8.96e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EGFR—colon cancer	2.24e-05	8.87e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HRAS—colon cancer	2.22e-05	8.8e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HRAS—colon cancer	2.21e-05	8.75e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—SRC—colon cancer	2.21e-05	8.75e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SRC—colon cancer	2.2e-05	8.71e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—colon cancer	2.15e-05	8.52e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KRAS—colon cancer	2.14e-05	8.49e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KRAS—colon cancer	2.14e-05	8.49e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KRAS—colon cancer	2.14e-05	8.49e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—colon cancer	2.14e-05	8.49e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—colon cancer	2.14e-05	8.49e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—colon cancer	2.14e-05	8.49e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—colon cancer	2.14e-05	8.48e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TGFB1—colon cancer	2.14e-05	8.47e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TGFB1—colon cancer	2.14e-05	8.47e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TGFB1—colon cancer	2.14e-05	8.47e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NRAS—colon cancer	2.12e-05	8.42e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—colon cancer	2.12e-05	8.41e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NRAS—colon cancer	2.11e-05	8.38e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KRAS—colon cancer	2.11e-05	8.38e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—colon cancer	2.11e-05	8.37e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—colon cancer	2.11e-05	8.37e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—colon cancer	2.11e-05	8.37e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TGFB1—colon cancer	2.11e-05	8.35e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—colon cancer	2.1e-05	8.33e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—colon cancer	2.09e-05	8.3e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—colon cancer	2.09e-05	8.3e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—colon cancer	2.09e-05	8.3e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—colon cancer	2.06e-05	8.19e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—EP300—colon cancer	2.06e-05	8.16e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—EP300—colon cancer	2.06e-05	8.16e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—EP300—colon cancer	2.06e-05	8.16e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—EP300—colon cancer	2.03e-05	8.04e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PIK3CA—colon cancer	2.01e-05	7.96e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PIK3CA—colon cancer	2e-05	7.92e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—colon cancer	1.98e-05	7.84e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KRAS—colon cancer	1.98e-05	7.84e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KRAS—colon cancer	1.98e-05	7.84e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KRAS—colon cancer	1.98e-05	7.84e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TGFB1—colon cancer	1.97e-05	7.82e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—colon cancer	1.97e-05	7.81e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PIK3CA—colon cancer	1.97e-05	7.8e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PIK3CA—colon cancer	1.97e-05	7.8e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PIK3CA—colon cancer	1.97e-05	7.8e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.97e-05	7.8e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TGFB1—colon cancer	1.96e-05	7.79e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—colon cancer	1.96e-05	7.77e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KRAS—colon cancer	1.95e-05	7.73e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—colon cancer	1.95e-05	7.73e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PIK3CA—colon cancer	1.94e-05	7.69e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—colon cancer	1.93e-05	7.67e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—colon cancer	1.93e-05	7.63e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CASP3—colon cancer	1.92e-05	7.61e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CASP3—colon cancer	1.92e-05	7.61e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CASP3—colon cancer	1.92e-05	7.61e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CASP3—colon cancer	1.89e-05	7.51e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCND1—colon cancer	1.87e-05	7.41e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCND1—colon cancer	1.87e-05	7.41e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCND1—colon cancer	1.87e-05	7.41e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CTNNB1—colon cancer	1.85e-05	7.34e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CTNNB1—colon cancer	1.85e-05	7.34e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CTNNB1—colon cancer	1.85e-05	7.34e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCND1—colon cancer	1.84e-05	7.31e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KRAS—colon cancer	1.83e-05	7.25e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CTNNB1—colon cancer	1.82e-05	7.23e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—colon cancer	1.82e-05	7.22e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—colon cancer	1.82e-05	7.22e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—colon cancer	1.82e-05	7.22e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KRAS—colon cancer	1.82e-05	7.21e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PIK3CA—colon cancer	1.82e-05	7.21e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PIK3CA—colon cancer	1.82e-05	7.21e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PIK3CA—colon cancer	1.82e-05	7.21e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1A—colon cancer	1.81e-05	7.17e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1A—colon cancer	1.81e-05	7.17e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1A—colon cancer	1.81e-05	7.17e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—colon cancer	1.8e-05	7.12e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PIK3CA—colon cancer	1.79e-05	7.1e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1A—colon cancer	1.78e-05	7.07e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EP300—colon cancer	1.72e-05	6.82e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EP300—colon cancer	1.72e-05	6.82e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EP300—colon cancer	1.72e-05	6.82e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EP300—colon cancer	1.7e-05	6.72e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—colon cancer	1.68e-05	6.67e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—colon cancer	1.68e-05	6.67e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—colon cancer	1.68e-05	6.67e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PIK3CA—colon cancer	1.68e-05	6.66e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SRC—colon cancer	1.67e-05	6.63e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SRC—colon cancer	1.67e-05	6.63e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SRC—colon cancer	1.67e-05	6.63e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PIK3CA—colon cancer	1.67e-05	6.63e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—colon cancer	1.66e-05	6.57e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SRC—colon cancer	1.65e-05	6.54e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—colon cancer	1.64e-05	6.5e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—colon cancer	1.63e-05	6.47e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—colon cancer	1.63e-05	6.46e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—colon cancer	1.63e-05	6.46e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—colon cancer	1.63e-05	6.46e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—colon cancer	1.62e-05	6.44e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—colon cancer	1.62e-05	6.41e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NRAS—colon cancer	1.61e-05	6.38e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NRAS—colon cancer	1.61e-05	6.38e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NRAS—colon cancer	1.61e-05	6.38e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—colon cancer	1.61e-05	6.38e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—colon cancer	1.61e-05	6.38e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—colon cancer	1.61e-05	6.38e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—colon cancer	1.61e-05	6.37e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—colon cancer	1.6e-05	6.34e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—colon cancer	1.6e-05	6.34e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—colon cancer	1.6e-05	6.34e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NRAS—colon cancer	1.59e-05	6.29e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—colon cancer	1.58e-05	6.29e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—colon cancer	1.58e-05	6.25e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—colon cancer	1.55e-05	6.16e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—colon cancer	1.55e-05	6.13e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CA—colon cancer	1.52e-05	6.03e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CA—colon cancer	1.52e-05	6.03e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CA—colon cancer	1.52e-05	6.03e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CA—colon cancer	1.5e-05	5.95e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—colon cancer	1.5e-05	5.94e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—colon cancer	1.5e-05	5.94e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—colon cancer	1.5e-05	5.94e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TGFB1—colon cancer	1.5e-05	5.93e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TGFB1—colon cancer	1.5e-05	5.93e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TGFB1—colon cancer	1.5e-05	5.93e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—colon cancer	1.48e-05	5.89e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—colon cancer	1.48e-05	5.89e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—colon cancer	1.48e-05	5.89e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—colon cancer	1.48e-05	5.86e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TGFB1—colon cancer	1.47e-05	5.85e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—colon cancer	1.47e-05	5.81e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—colon cancer	1.47e-05	5.81e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—colon cancer	1.47e-05	5.81e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—colon cancer	1.46e-05	5.8e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—colon cancer	1.45e-05	5.73e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KRAS—colon cancer	1.38e-05	5.49e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KRAS—colon cancer	1.38e-05	5.49e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KRAS—colon cancer	1.38e-05	5.49e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—colon cancer	1.37e-05	5.44e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KRAS—colon cancer	1.37e-05	5.41e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—colon cancer	1.36e-05	5.41e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TYMS—colon cancer	1.31e-05	5.18e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CA—colon cancer	1.27e-05	5.05e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CA—colon cancer	1.27e-05	5.05e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CA—colon cancer	1.27e-05	5.05e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CA—colon cancer	1.25e-05	4.97e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—colon cancer	1.24e-05	4.93e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—colon cancer	1.24e-05	4.93e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—colon cancer	1.24e-05	4.93e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—colon cancer	1.23e-05	4.88e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—colon cancer	1.23e-05	4.88e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—colon cancer	1.23e-05	4.88e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—colon cancer	1.23e-05	4.86e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—colon cancer	1.21e-05	4.81e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—colon cancer	1.18e-05	4.67e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—colon cancer	1.18e-05	4.67e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—colon cancer	1.18e-05	4.67e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—colon cancer	1.16e-05	4.6e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—colon cancer	1.04e-05	4.12e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—colon cancer	1.04e-05	4.12e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—colon cancer	1.04e-05	4.12e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—colon cancer	1.02e-05	4.06e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARG—colon cancer	9.25e-06	3.67e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTGS2—colon cancer	7.28e-06	2.89e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—EP300—colon cancer	6.05e-06	2.4e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CA—colon cancer	4.48e-06	1.78e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—colon cancer	3.66e-06	1.45e-05	CbGpPWpGaD
